MEDICAL

AvantGen Announces Licensing of its anti-SARS-CoV-2 Antibody Clones to IGM Biosciences for COVID-19 Therapy Development

AvantGen | January 12, 2021

AvantGen, Inc., a San Diego-based biotechnology organization with a variety of innovation stages for neutralizer revelation and enhancement, and novel NK and T cell engager age, today reported permitting of a board of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Utilizing its novel yeast show framework and huge different human antibody response libraries, AvantGen has distinguished a board of high partiality human monoclonal antibody clones that quandary to two unmistakable epitopes on the receptor restricting space of the SARS-CoV-2 spike protein. After official, the antibodies block the spike protein from cooperating with ACE2 and subsequently forestall infection prompted cell-slaughtering, otherwise called cytopathic impact. Furthermore, one gathering of immune response clones can likewise obstruct ACE2's cooperation with SARS-CoV-1, showing that the epitope perceived by this gathering of clones is rationed between SARS-CoV-1 and - 2, conceivably presenting more extensive killing action against this family of coronaviruses.

In a recognized animal model of SARS-CoV-2 contamination, AvantGen's lead applicant antibody has been appeared to fundamentally diminish viral load in, and macrophage infiltration of, the lungs, as well as reduce disease severity.

Spotlight

When a cell divides, it needs to copy its entire genome accurately and make sure each of the two new daughter When a cell divides, it needs to copy its entire genome accurately and make sure each of the two new daughter cells receives a complete set of chromosomes. But cells can make mistakes, and bits of chromosomes can get swapped around, lost, or copied too often. This genetic chaos is called Chromosomal Instability. If there is too much chromosomal instability in a cell, signals by DNA-checking proteins cause the cell to self-destruct. But cancer cells seem to be able to accumulate chromosomal instability without self-destructing. This leads to a lot of genetic diversity in a tumour, making them hard to treat.

Spotlight

When a cell divides, it needs to copy its entire genome accurately and make sure each of the two new daughter When a cell divides, it needs to copy its entire genome accurately and make sure each of the two new daughter cells receives a complete set of chromosomes. But cells can make mistakes, and bits of chromosomes can get swapped around, lost, or copied too often. This genetic chaos is called Chromosomal Instability. If there is too much chromosomal instability in a cell, signals by DNA-checking proteins cause the cell to self-destruct. But cancer cells seem to be able to accumulate chromosomal instability without self-destructing. This leads to a lot of genetic diversity in a tumour, making them hard to treat.

Related News

MEDTECH

IBM Research and Arctoris accelerate closed loop drug discovery with AI and Cloud

Arctoris | September 14, 2021

IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System), the system is able to perform highly accurate reaction predictions using its powerful AI. Optimised synthetic routes are then used as input for RoboRXN, an automated platform for molecule synthesis. Arctoris has developed Ulysses, an end-to-end automated platform for drug discovery research. The platform ensures accuracy, precision, and reproducibility by leveraging robotic experiment execution and digital data capture technologies across cell and molecular biology and biochemistry/biophysics. Experiments conducted with Ulysses generate more than 100 times more datapoints per assay compared to industry standard, leading to deeper insights and accelerated progress compared to manual methods. The two platforms are now being combined for the first time in a research collaboration that will see new small molecule inhibitors for undisclosed targets being designed, made, tested, and analysed (DMTA) in an autonomous, closed loop approach. Concretely, IBM Research will design and synthesize novel chemical matter (Design, Make), to be profiled and evaluated by Arctoris (Test, Analyze), with the resulting data informing the subsequent iteration of the DMTA cycle. The collaboration is currently on-going; financial terms were not disclosed. About IBM Research For more than seven decades, IBM Research has defined the future of information technology with more than 3,000 researchers in 16 locations across five continents. Scientists from IBM Research have produced six Nobel Laureates, 10 U.S. National Medals of Technology, five U.S. National Medals of Science, six Turing Awards, 19 inductees in the National Academy of Sciences and 20 inductees into the U.S. National Inventors Hall of Fame. About Arctoris Arctoris is a biotechnology company founded and headquartered in Oxford with additional operations in Boston and Singapore. Ulysses, the unique technology platform developed by Arctoris, enables the company to conduct its R&D – from target via hit and lead to candidate – significantly faster, and with considerably improved data quality and depth. With its robotics, Arctoris generates richer, more reliable data, enabling better decisions both in human-driven and computational drug discovery, leading to higher success rates and an accelerated progression of programs towards the clinic. Led by an experienced team, Arctoris pursues its internal pipeline of small molecule inhibitors in different indications, and also partners with other biotech and pharma companies for small molecule and biologics discovery, with partners in the US, UK, Germany, Australia, Korea, China, and several other countries.

Read More

INDUSTRY OUTLOOK

Andelyn Biosciences Selects TetraScience as a Strategic Partner for Innovation in Therapeutics Development and Manufacturing

Andelyn Biosciences | August 26, 2021

TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers. As part of an Andelyn Biosciences initiative to create a Connected Plant that harmonizes data from building and facilities, process and manufacturing, and lab instrument sources, TDP will enable better compliance, easier analysis, faster decisions, and more agile operations. Additionally, Andelyn customers will benefit from secure, convenient access to harmonized data that is prepared for analytics and visualization. As a Contract Development and Manufacturing Organization (CDMO) for cell and gene therapies, Andelyn must remain GMP-compliant and increase efficiency while leading the industry in the innovative services they provide to customers. By launching a Connected Plant, Andelyn will gain autonomous operation, predictive capabilities, improved process monitoring and control, and increased data integrity. "Andelyn has been a pioneer in gene therapy with a 15-year history accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients," said Bryan J. Holmes, Vice President, Information Technology at Andelyn Biosciences. "Together with TetraScience, we're transforming how we work with our clients, utilizing fully-digitized, cloud-native services to help connect all the plant and lab data created during complex development and manufacturing cycles." Andelyn chose TDP for its unique ability to harmonize data from building & facilities systems, lab instruments, and process & manufacturing equipment. By replatforming the data to a future-proof managed cloud environment, Andelyn will benefit from enhanced GMP compliance and data integrity, improved time-to-value, and lower TCO. Additionally, with an open data cloud platform powered by TDP and the Tetra Partner Network, Andelyn will be able to leverage their preferred tooling for analytics while supporting their customers' data consumption needs. "We're excited to partner with Andelyn Biosciences on their mission-critical data cloud initiative and accelerate their journey towards becoming a digital company," stated Chad Garrett, TetraScience CRO. "As an innovator in providing cloud-native development and manufacturing services to its customers, Andelyn Biosciences recognizes that harmonizing scientific data in the cloud and making it easily accessible to clients will transform the way CDMOs exchange data with clients." Andelyn's initial deployment of TDP is focused on acquiring and harmonizing historical data across key sources while enabling enhanced data search capabilities. Moving forward, Andelyn expects to complete the rollout of the Connected Plant with additional data sources and instruments, and ultimately launch a groundbreaking digital CDMO experience for their customers. About Andelyn Biosciences, Inc. Andelyn Biosciences is a pioneering gene therapy company born out of Nationwide Children's Hospital, where the first FDA-approved systemic gene therapy was discovered. Andelyn is named in honor of two gene therapy pioneers who participated in pivotal Phase I clinical trials at Nationwide Children's Hospital 8-year-old Andrew and 8-week-old Evelyn. Bringing together more than 15 years of experience in AAV vector manufacturing, Andelyn is a full-spectrum Contract Development Manufacturing Organization (CDMO) that helps pioneer solutions that turn hope into reality. Our mission is to accelerate the development and manufacturing of innovative therapies to bring more treatments to more patients. We accomplish this by bringing scalability, capacity, efficiency and expert resources to manufacturing matrices, all to advance the development of viral vector-based therapeutics. Our capabilities include viral vector process and analytical development, small to large scale GMP manufacturing, fill/finish and QC/QA release testing through Phase III with plans to launch commercial services in 2022. Andelyn also offers plasmid manufacturing services, formulation development services and regulatory support.

Read More

RESEARCH

Bio-Techne And Carterra Initiate A Clinical Research Collaboration For COVID-19 Variant Analysis

Bio-Techne Corporation | September 08, 2021

Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screening and characterization, today announced a clinical research collaboration studying COVID-19 variants. New variants, such as Delta, can be more easily transmitted and more likely to evade the immune response of vaccinated or previously infected people. To assess immune responses to new variants and to plan for intervention mechanisms that avoid vaccine escape, scientists and epidemiologists need a fast and effective assay. The partnership leverages Carterra's flagship analytical platform - the LSA® - to characterize panels of SARS-CoV-2 spike and receptor-binding domain (RBD) variants in an information-rich assay. The SARS-CoV-2 variants were developed by Bio-Techne and used to fast-track the new, scalable assay for measuring the potential risks that new variants may evade the ability of the immune system to block the virus. Bio-Techne has been leading the way in COVID-19 research reagent and immunoassay development enabling scientists to make discoveries leading to effective diagnoses, therapies and vaccines. The company was first to market with COVID-19 research protein variants and has significant expertise with SARS-CoV-2 antibody quantitation. Bio-Techne and Carterra will focus this collaboration on more than 40 variants, including the Delta variant that is prevalent today, and emerging variants as they are discovered. The Carterra LSA will be used to generate high-definition insights with over 120 data points from patient serum samples, including a variant profile, ACE-2 blocking potential, and isotyping profiles of immunoglobin response. The LSA's hands-free, high-throughput setup requires only 2 µL of patient serum and provides for the analysis of new and emerging variants in the ever-evolving field of COVID-19 research. Carterra's LSA instrument is the fastest, most sensitive and flexible biosensor platform on the market. Combining proprietary flow printing microfluidics with High Throughput Surface Plasmon Resonance (HT-SPR) technology, the LSA enables detailed screening and characterization of vast antibody or variant libraries, including full kinetic profiles. With the ability to generate real-time binding data for 384 proteins on one chip and assay up to 1152 patient samples in a single unattended run, the LSA significantly improves efficiency and speed in both drug discovery and clinical research. About Bio-Techne Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $931 million in net sales in fiscal 2021 and has approximately 2,700 employees worldwide. About Carterra, Inc. Carterra® is the leading provider of high throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra's LSA™ instrument, software, and consumables for monoclonal antibody (mAb) characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems. The LSA combines patented microfluidics technology with real-time high throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, and Munich, Germany.

Read More